621 studies on Semaglutide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This review underscores a transformative era in obesity management, moving beyond modest weight loss to therapies offering substantial and sustained reductions. The comprehensive overview provided by the authors is cr…
This comprehensive systematic review provides robust evidence that GLP-1 receptor agonists are highly effective and generally safe pharmacological interventions for significant weight loss in adults without diabetes. …
This comprehensive quantitative comparison provides invaluable evidence for clinicians and patients, offering clear guidance on the expected weight loss from different GLP-1 RAs. The findings underscore the varying po…
This systematic review underscores the rapid evolution of pharmacotherapy for obesity, offering unprecedented hope for effective and substantial weight management. The identified therapies, particularly multi-agonist …
This comprehensive network meta-analysis provides crucial evidence to guide clinical decision-making, offering a head-to-head comparison of incretin drugs that is often unavailable from direct trials. The finding that…
This study provides crucial, evidence-based insights into the comparative efficacy and safety of available GLP-1 RAs, offering a clear hierarchy of their weight reduction capabilities. The findings highlight that newe…
This systematic review provides compelling evidence for the superior efficacy of semaglutide among current pharmacological options for obesity management. The substantial weight loss achieved with semaglutide, a GLP-1…
Antiobesity medications offer a dual therapeutic strategy for managing both obesity and the often-coexisting MASLD, a condition with limited approved treatments. This review highlights their potential to become a corn…
This comprehensive NMA provides crucial evidence supporting the superior efficacy of multi-receptor agonists like retatrutide and tirzepatide over single GLP-1 RAs for significant weight loss in adults with overweight…
This study provides compelling evidence that GLP-1 receptor agonists, particularly the more potent multi-agonists, could represent a novel and effective therapeutic class for Alcohol Use Disorder (AUD). By attenuating…
This review underscores the rapid evolution of pharmacotherapy for obesity, moving beyond traditional approaches to highly effective hormonal analogues that mimic natural satiety signals. The findings suggest a future…
This review critically underscores the importance of a holistic and integrated approach to weight management when utilizing powerful pharmacological tools like GLP-1 RAs. Preserving muscle mass is not merely an aesthe…
This comprehensive review highlights the transformative potential of anti-obesity drugs in managing and potentially reversing MASLD, moving beyond mere lifestyle interventions to address underlying liver pathology. Th…
This review underscores the transformative potential of novel GLP-1-based medications to significantly advance the treatment of Type 2 Diabetes and Obesity. The enhanced efficacy in weight loss and glycemic control, c…
This comprehensive review highlights the significant therapeutic potential of GLP-1 agonists as a multi-faceted treatment for PCOS, addressing not only metabolic dysfunction like insulin resistance and obesity but als…
This review provides a crucial, up-to-date resource for healthcare providers, offering a clear understanding of the current landscape of obesity pharmacotherapy. It underscores the paradigm shift towards highly effect…
These advancements collectively represent a significant leap forward in nephrology, offering new hope for patients with various kidney conditions. The expansion of complement inhibitors and the efficacy of GLP-1 recep…
The findings from this study are profoundly significant, as they identify retatrutide as a potentially superior therapeutic agent for MC4R-deficient obesity, a condition notoriously difficult to manage. This MC4R defi…
This research highlights a critical public health concern stemming from the proliferation of unregulated compounded GLP-1 RAs sold directly to consumers. The findings underscore the substantial potential for patient s…
Understanding the precise chemical structure and identity of compounds like semaglutide is absolutely critical for pharmaceutical development, ensuring drug purity, consistency, and regulatory compliance. This detaile…
This upcoming clinical trial holds significant promise for patients battling both Type 2 Diabetes and Coronary Arterial Disease, a population at high risk for severe cardiovascular events. If successful, the findings …
This review highlights a rapidly evolving therapeutic landscape for MASLD in T2D, moving towards integrated metabolic, hepatic, and cardiovascular risk reduction. The identification of agents like semaglutide and resm…